Kathryn P. Componeschi

Statistics

Publications

Citations

601

H-Index

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

Beth Israel Deaconess Medical Center

Baylor College of Medicine

UPMC Hillman Cancer Center

Johns Hopkins University

Kathryn P. Componeschi is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and human epidermal growth factor receptor 2-targeted therapy.

Publications per year

2011–2020

Publications

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Rachel A. Freedman, Rebecca Gelman, Carey K. Anders et al. · Journal of Clinical Oncology · 2019 · 338 citations · Full text

Medicine, Oncology, Pharmacology +17

PALB2 mutations in familial breast and pancreatic cancer

Erin Hofstatter, Susan M. Domchek, Alexander Miron et al. · Familial Cancer · 2011 · 156 citations · Full text

Medicine, Genetics, Oncology +14

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

Erica L. Mayer, Vandana G. Abramson, Rachel C. Jankowitz et al. · Annals of Oncology · 2020 · 80 citations · Full text

Medicine, Molecular Biology, Oncology +14

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022

Rachel A. Freedman, Rebecca Gelman, Nathalie Y.R. Agar et al. · Clinical Breast Cancer · 2019 · 27 citations · Full text

Medicine, Oncology, Surgery +14

1–4 of 4